Tuesday, June 02, 2009

Sanofi's PARP inhibitor

Sanofi-Aventis bought BiPar to obtain rights to BiPar's BSI-201, which belongs to a new class of drugs that block a cell repair enzyme known as PARP. An issue is that BiPar's main composition patent in the US runs out in 2013, although it might be extended.


Post a Comment

<< Home